相关实验视频

Updated: Sep 15, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

在骨髓瘤中逆转MPPa-PDT抵抗,通过准ROCK2-介导的自

Xuan Yi^1,2,3,4, Xueqiang Deng^1,5, Jianyong Deng⁶

¹Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Cell proliferation

|July 16, 2025

概括

向含有Rho相关的卷-卷蛋白激酶2 (ROCK2) 逆转了骨髓瘤中对pyropheophorbide-a甲基光动力疗法 (MPPa-PDT) 的耐药性. 抑制ROCK2降低了自和恢复MPPa-PDT敏感性,为骨髓瘤提供了新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

骨肉瘤 (OS) 是一种具有不良预后的恶性骨瘤,通常会对像pyropheophorbide-a methyl ester-Photodynamic therapy (MPPa-PDT) 这样的治疗产生耐药性.
了解MPPa-PDT耐药性的机制对于改善骨髓瘤患者治疗结果至关重要.

研究的目的:

为了研究含有蛋白激酶2 (ROCK2) 的Rho相关卷绕卷轴在骨髓瘤中MPPa-PDT耐药性的作用.
阐明ROCK2影响MPPa-PDT敏感性的分子机制,重点关注自和Hippo信号通路.

主要方法:

在MPPa-PDT治疗后的骨髓瘤细胞中评估ROCK2表达.
研究了ROCK2抑制对骨髓瘤细胞对MPPa-PDT和细胞自水平敏感性的影响.
进行了救援实验,以确认ROCK2在通过自调节调解抵抗中的作用.
在Hippo信号通路中分析了ROCK2,SAV1和MST1之间的相互作用.
与临床骨髓瘤患者预后相关的ROCK2表达和Hippo通路活性.

主要成果:

在MPPa-PDT治疗后,骨髓瘤细胞中ROCK2表达被上调.
抑制ROCK2对MPPa-PDT敏感的骨髓瘤细胞,并降低了自.
发现ROCK2通过Hippo信号通路调节自,以调节MPPa-PDT抵抗.
在SAV1结合方面,ROCK2与MST1竞争,抑制Hippo通路激活,并促进MPPa-PDT耐药性.
临床数据证实ROCK2是一种独立的预后因素,与骨髓瘤患者的恶化结果有关.

结论:

ROCK2通过通过Hippo信号通路调节自,在骨髓瘤中调解MPPa-PDT抗性的过程中起着至关重要的作用.
针对性抑制ROCK2,例如使用J059-0149,是克服MPPa-PDT耐药性的有希望的策略.
这项研究为提高MPPa-PDT在骨髓瘤治疗中的临床疗效提供了新的治疗目标和见解.

关键词:

在MPPa-PDT之间.在Rock2上,我一直在努力.自自是自的过程.河马的路径河马的路径骨质肉瘤是骨质肉瘤的一种疾病.

更多相关视频

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...